HIV patients and GcMAF
“Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)”
Stepwise treatment of purified Gc protein with immobilized -galactosidase and sialidase generated the most potent macrophage activating factor (termed GcMAF), which produces no side effects in humans. Macrophages activated by administration of 100 ng GcMAF develop a large amount of Fc-receptors as well as an enormous variation of receptors that recognize IgG-bound and unbound HIV virions.
Since latently HIV-infected cells are unstable and constantly release HIV virions, the activated macrophages rapidly intercept the released HIV virions to prevent reinfection resulting in exhaustion of infected cells.
After less than 18 weekly administrations of 100 ng GcMAF for nonanemic patients, they exhibited low serum Nagalase activities equivalent to healthy controls, indicating eradication of HIV-infection, which was also confirmed by no infectious center formation by provirus inducing agent-treated patient PBMCs. No recurrence occurred and their healthy CD + cell counts were maintained for 7 years. J. Med. Virol. 81:16-26, 2009.
© 2008 Wiley-Liss, Inc.
2Nakagawa Hospital, Fukuoka City, Japan
*Correspondence to Nobuto Yamamoto, Division of Molecular Immunology and Immunotherapy, Socrates Institute for Therapeutic Immunology, 1040 66th Ave., Philadelphia, PA 19126-3305.
US Public Health Service (partial support); Grant Number: AI-32140
Elsa U. Pardee Foundation (to N.Y.)
macrophages • macrophage activation • eradication of HIV • immunosuppression
Accepted: 18 September 2008